Steve Blank

article thumbnail

Reinventing Life Science Startups–Therapeutics and Diagnostics

Steve Blank

For exits, acquisitions are the rule and IPOs the exception. Using high-throughput screening to search for small molecules, which can be a starting point (or lead compound) for a new drug, scientists can test thousands of candidate molecules against a database of millions in their libraries.